Search Results for: PDGFRB

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CAV1 caveolin 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Congenital generalized lipodystrophy (CGL)
CBL Cbl proto-oncogene
  • Interleukin-6 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Spry regulation of FGF signaling
  • Regulation of KIT signaling
  • EGFR downregulation
  • TGF-beta receptor signaling activates SMADs
  • Constitutive Signaling by EGFRvIII
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Negative regulation of MET activity
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Negative regulation of FLT3
  • FLT3 signaling by CBL mutants
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
JAK2 Janus kinase 2
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • Prolactin receptor signaling
  • Prolactin receptor signaling
  • Signaling by SCF-KIT
  • Signaling by Leptin
  • RMTs methylate histone arginines
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF activation
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Cyclin D associated events in G1
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Regulation of IFNG signaling
  • Interleukin-20 family signaling
  • Interleukin-35 Signalling
  • Signaling by Erythropoietin
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Interleukin receptor SHC signaling
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Potential therapeutics for SARS
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Factors involved in megakaryocyte development and platelet production
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • XL019
  • 5-phenyl-1H-indazol-3-amine
  • 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
  • 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Entrectinib
  • Fostamatinib
  • Fedratinib
  • Zanubrutinib
  • Pralsetinib
  • Polycythemia vera
PDGFRA platelet derived growth factor receptor alpha
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Imatinib-resistant PDGFR mutants
  • Sunitinib-resistant PDGFR mutants
  • Regorafenib-resistant PDGFR mutants
  • Sorafenib-resistant PDGFR mutants
  • PDGFR mutants bind TKIs
  • Becaplermin
  • Imatinib
  • Sunitinib
  • XL820
  • Olaratumab
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Foreskin keratinocyte (neonatal)
  • Fostamatinib
  • Erdafitinib
  • Amuvatinib
  • Ripretinib
  • Glioma
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • ATP
  • Caffeine
  • XL765
  • Wortmannin
  • Pilaralisib
  • Alpelisib
  • Copanlisib
  • Ovarian cancer
PTPN2 protein tyrosine phosphatase non-receptor type 2
  • Negative regulation of MET activity
  • Interleukin-37 signaling
  • Type I diabetes mellitus
RASA1 RAS p21 protein activator 1
  • Downstream signal transduction
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • VEGFR2 mediated cell proliferation
  • Regulation of RAS by GAPs
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
SLC9A3R1 SLC9A3 regulator 1
  • Nephrolithiasis/osteoporosis, hypophosphatemic
STAT5B signal transducer and activator of transcription 5B
  • Prolactin receptor signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Signaling by Leptin
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-2 signaling
  • Interleukin-21 signaling
  • Erythropoietin activates STAT5
  • STAT5 Activation
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 fusion proteins
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Dasatinib
  • Growth hormone insensitivity with immunodeficiency
SYNGAP1 synaptic Ras GTPase activating protein 1
  • Regulation of RAS by GAPs
  • Non-syndromic autosomal dominant mental retardation
TYK2 tyrosine kinase 2
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • Other interleukin signaling
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Interleukin-20 family signaling
  • Interleukin-35 Signalling
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Interferon alpha/beta signaling
  • Regulation of IFNA signaling
  • Regulation of IFNA signaling
  • Potential therapeutics for SARS
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • Tofacitinib
  • Fostamatinib
  • Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
ABL2 ABL proto-oncogene 2, non-receptor tyrosine kinase
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Negative regulation of FLT3
  • ATP
  • Dasatinib
  • XL228
  • K-00546
  • Fostamatinib
BAG1 BAG cochaperone 1
  • Regulation of HSF1-mediated heat shock response
  • (2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
CEP76 centrosomal protein 76
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • AURKA Activation by TPX2
COPA COPI coat complex subunit alpha
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
COPB1 COPI coat complex subunit beta 1
  • Neutrophil degranulation
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
CRK CRK proto-oncogene, adaptor protein
  • ARMS-mediated activation
  • ARMS-mediated activation
  • Downstream signal transduction
  • Regulation of actin dynamics for phagocytic cup formation
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Regulation of signaling by CBL
  • FCGR3A-mediated phagocytosis
EIF2AK2 eukaryotic translation initiation factor 2 alpha kinase 2
  • ISG15 antiviral mechanism
  • Inhibition of PKR
  • Fostamatinib
FYN FYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by ERBB2
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Nephrin family interactions
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • VEGFA-VEGFR2 Pathway
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Platelet Adhesion to exposed collagen
  • Reelin signalling pathway
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • Triglyme
  • Fostamatinib
GAB1 GRB2 associated binding protein 1
  • PI3K Cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • MET activates PTPN11
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants

Page 2 out of 5 pages